NASDAQ · IKNA
Ikena Oncology, Inc.
$17.16+$15.79 (+1,152.55%)
Ikena Oncology, Inc.’s quoted price sits in the upper half of its reported 52-week range, 26.29% below the high.
Loading market information…
NASDAQ · SAGE · USD
Stock price, earnings
Quote as of Jul 31, 2025, 08:00 PM UTC. Cached market data; not a live quote.
One-year closing-price history · USD. Historical prices are not a forecast.
Sage Therapeutics, Inc.’s quoted price sits in the upper half of its reported 52-week range, 7.26% below the high.
52-week range
Go beyond this overview with deeper company research in PortfolioX. Explore more in the app
BEHIND THE RESULTS
Upcoming dates and analyst estimates may change. Fiscal quarters follow Sage Therapeutics, Inc.’s reporting calendar.
THE COMPANY BEHIND THE TICKER
Sage Therapeutics, Inc. functions as a biopharmaceutical enterprise, dedicated to the discovery, development, and market introduction of therapeutic agents aimed at central nervous system (CNS) conditions. Its primary medication is ZULRESSO, an intravenous form of brexanolone, prescribed for the treatment of postpartum depression (PPD) in adult patients. The company's advanced pipeline includes zuranolone, a neuroactive steroid, which is presently undergoing Phase III clinical trials for several disorders, such as PPD, major depressive disorders, treatment-resistant depression, generalized anxiety disorders, and bipolar depression. Another investigational compound, SAGE-324, is in Phase II studies for essential tremors, having already completed Phase I trials for epilepsy and Parkinson's disease. Furthermore, SAGE-718, an oxysterol-based positive allosteric modulator of the NMDA receptor, has concluded its Phase I clinical assessments for a range of indications including depression, Huntington's disease, Alzheimer's disease, attention deficit hyperactivity disorder, schizophrenia, and neuropathic pain. To enhance its global reach and innovative efforts, Sage Therapeutics has established significant collaborations. This comprises a strategic partnership with Shionogi & Co., Ltd. for the advancement and commercialization of zuranolone in Japan, Taiwan, and South Korea. Additionally, the company holds a collaboration and licensing agreement with Biogen MA Inc. for the joint development and marketing of its SAGE-217 and SAGE-324 products. Incorporated in 2010 and based in Cambridge, Massachusetts, the firm was initially known as Sterogen Biopharma, Inc., before officially changing its name to Sage Therapeutics, Inc. in September 2011.
Latest available per-share figures in USD. The payout ratio compares dividends with earnings.
About this data · PortfolioX market data, also available in the mobile app. Prices are displayed in the listing currency; dividend amounts use the currency shown in that section. Data availability and update times vary.
Page generated Oct 30, 2026, 03:47 PM UTC. Quotes retain their own timestamp above. Missing values appear as a dash. This page is for information only, not personalized investment advice.
| Q4 2023 | Feb 14, 2024 | -$0.55+53.39% vs estimate | $77.97M+27.86% vs estimate |
|---|
| Q3 2023 | Nov 7, 2023 | -$2.81-6.44% vs estimate | $2.72M-69.45% vs estimate |
|---|
THE ANALYST VIEW
36 ratings in the current snapshot. Strong buy and strong sell are grouped with buy and sell.
Percentages compare targets with the quoted price when currencies match. Targets are analyst estimates, not guaranteed outcomes.
HOW THE BUSINESS IS PERFORMING
Statement amounts use the company’s reporting currency and are not converted to the stock’s listing currency. K = thousand, M = million, B = billion, T = trillion. Cash-flow figures are matched by fiscal year; missing figures appear as a dash.
PUT THE NUMBERS IN CONTEXT
Current metrics alongside available historical medians. A lower multiple or higher margin alone does not establish whether a stock is a good investment.
KEEP COMPARING
$17.16+$15.79 (+1,152.55%)
Ikena Oncology, Inc.’s quoted price sits in the upper half of its reported 52-week range, 26.29% below the high.
$4.84$0.00 (0.0%)
Exscientia plc: Healthcare · Biotechnology.
$10.23-$0.11 (-1.02%)
Climb Bio, Inc.’s quoted price sits in the upper half of its reported 52-week range, 44.19% below the high.
$8.16$0.00 (0.0%)
Regulus Therapeutics Inc.’s quoted price sits in the upper half of its reported 52-week range, 2.22% below the high.
$6.47$0.00 (0.0%)
Sinovac Biotech Ltd.: Healthcare · Medical - Pharmaceuticals.
$10.15+$0.02 (+0.2%)
iTeos Therapeutics, Inc.’s quoted price sits in the lower half of its reported 52-week range, 42.43% below the high.
$3.65$0.00 (0.0%)
Revance Therapeutics, Inc.’s quoted price sits in the lower half of its reported 52-week range, 51.72% below the high.
$3.48-$0.18 (-4.8%)
ARS Pharmaceuticals, Inc.’s quoted price sits in the lower half of its reported 52-week range, 73.5% below the high.
